ethyl 3-(4-(2-aminoethoxy)phenyl)-2-ethoxypropionate | 220746-95-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 3-(4-(2-aminoethoxy)phenyl)-2-ethoxypropionate
• 英文别名: 3-[4-(2-aminoethoxy)phenyl]-2-ethoxypropionic acid ethyl ester；ethyl 3-(4-(2-aminoethoxy)phenyl)-2-ethoxypropanoate；ethyl 3-[4-(2-aminoethoxy)phenyl]-2-ethoxypropanoate
• CAS: 220746-95-2
• 化学式: C₁₅H₂₃NO₄
• 分子量: 281.352
• InChiKey: DLXYWFRCQQKCHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 3-(4-(2-aminoethoxy)phenyl)-2-ethoxypropionate 在 20percent aq. NaOH 作用下， 以 乙醇 为溶剂， 反应 160.0h， 生成 3-{4-[2-(Dibenzo[b,f][1,4]thiazepin-11-ylamino)-ethoxy]-phenyl}-2-ethoxy-propionic acid
  参考文献：
  名称：

  Novel Tricyclic-α-alkyloxyphenylpropionic Acids:  Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity

  摘要：

  Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC50 = 0.36 muM) and PPARgamma (EC50 = 0.17 muM) activity in vitro. Ten days treatment of db/db mice with 3q improved the insulin sensitivity, as measured by OGTT, better than that seen with both pioglitazone and rosiglitazone treatment, suggesting in vivo PPARgamma activity. Likewise, 3q lowered plasma triglycerides and cholesterol in high cholesterol fed rats after 4 days treatment, indicating in vivo PPARalpha activity. Investigations of the pharmacokinetics of selected compounds suggested that extended drug exposure improved the in vivo activity of in vitro active compounds.

  DOI：

  10.1021/jm010964g
• 作为产物：
  描述：

  2-乙氧基-3-对羟基苯基丙酸乙酯 在 potassium carbonate 、 potassium phtalimide 作用下， 以 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 反应 66.0h， 生成 ethyl 3-(4-(2-aminoethoxy)phenyl)-2-ethoxypropionate
  参考文献：
  名称：

  Novel Tricyclic-α-alkyloxyphenylpropionic Acids:  Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity

  摘要：

  Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC50 = 0.36 muM) and PPARgamma (EC50 = 0.17 muM) activity in vitro. Ten days treatment of db/db mice with 3q improved the insulin sensitivity, as measured by OGTT, better than that seen with both pioglitazone and rosiglitazone treatment, suggesting in vivo PPARgamma activity. Likewise, 3q lowered plasma triglycerides and cholesterol in high cholesterol fed rats after 4 days treatment, indicating in vivo PPARalpha activity. Investigations of the pharmacokinetics of selected compounds suggested that extended drug exposure improved the in vivo activity of in vitro active compounds.

  DOI：

  10.1021/jm010964g

文献信息

• Compounds, their preparation and use
  申请人：Novo Nordisk A/S

  公开号：US06214820B1

  公开（公告）日：2001-04-10

  The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及式（I）的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、A、X、T、Q、Z、U、Y、Ar、p和n如规范中定义。这些化合物在治疗和/或预防由核受体介导的疾病中有用，特别是过氧化物酶体增殖激活受体（PPAR）。
• Novel propionic acid derivatives
  申请人：——

  公开号：US20040072690A1

  公开（公告）日：2004-04-15

  A compound represented by the following formula (1) or a salt thereof: 1 wherein R 1 represents a C 1-12 alkyl group, phenyl group, 1-naphthyl group and the like, R 2 represents a C 2-12 alkyl group, (R 3 ) b represents 0 to 4 substituents such as a halogen atom, R 4 represents a lower alkyl group, R 5 represents hydrogen atom or a lower alkyl group, n represents an integer from 2 to 4, and X represents —NH— or —O—, which has superior hypoglycemic action, hypolipidemic action and total cholesterol reducing action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of diseases including diabetes mellitus, hyperlipidemia and the like.

  以下化合物的分子式（1）或其盐：其中R1代表C1-12烷基基团、苯基、1-萘基等，R2代表C2-12烷基基团，（R3）b代表0至4个卤原子等取代基，R4代表较低的烷基基团，R5代表氢原子或较低的烷基基团，n代表2至4的整数，X代表—NH—或—O—，具有优越的降糖作用、降脂作用和总胆固醇降低作用，可用作预防和/或治疗糖尿病、高脂血症等疾病的药物的活性成分。
• New compounds, their preparation and use
  申请人：——

  公开号：US20010029256A1

  公开（公告）日：2001-10-11

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , A, X, T, Q, Z, U, Y, Ar, p and n are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及式(I)1的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、A、X、T、Q、Z、U、Y、Ar、p和n的定义如规范中所述。这些化合物在治疗和/或预防由核受体介导的疾病中有用，特别是过氧化物酶体增殖物激活受体（PPAR）。
• Propionic acid derivatives
  申请人：Asahi Kasei Pharma Corporation

  公开号：US07015345B2

  公开（公告）日：2006-03-21

  A compound represented by the following formula (1) or a salt thereof: wherein R1 represents a C1-12 alkyl group, phenyl group, 1-naphthyl group and the like, R2 represents a C2-12 alkyl group, (R3)b represents 0 to 4 substituents such as a halogen atom, R4 represents a lower alkyl group, R5 represents hydrogen atom or a lower alkyl group, n represents an integer from 2 to 4, and X represents —NH— or —O—, which has superior hypoglycemic action, hypolipidemic action and total cholesterol reducing action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of diseases including diabetes mellitus, hyperlipidemia and the like.

  以下化合物式（1）或其盐代表的化合物：其中R1代表C1-12烷基，苯基，1-萘基等，R2代表C2-12烷基，(R3)b代表0到4个取代基，例如卤素原子，R4代表较低的烷基，R5代表氢原子或较低的烷基，n代表2到4的整数，X代表-NH-或-O-，具有优越的降血糖作用、降血脂作用和总胆固醇降低作用，并且作为药物的活性成分，用于预防和/或治疗糖尿病、高脂血症等疾病。
• NOVEL PROPIONIC ACID DERIVATIVE
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1484316A1

  公开（公告）日：2004-12-08

  A compound represented by the following formula (1) or a salt thereof: wherein R1 represents a C1-12 alkyl group, phenyl group, 1-naphthyl group and the like, R2 represents a C2-12 alkyl group, (R3)b represents 0 to 4 substituents such as a halogen atom, R4 represents a lower alkyl group, R5 represents hydrogen atom or a lower alkyl group, n represents an integer from 2 to 4, and X represents -NH- or -O-, which has superior hypoglycemic action, hypolipidemic action and total cholesterol reducing action, and is useful as an active ingredient of a medicament for prophylactic and/or therapeutic treatment of diseases including diabetes mellitus, hyperlipidemia and the like.

  下式（1）代表的化合物或其盐： 其中 R1 代表 C1-12 烷基、苯基、1-萘基等，R2 代表 C2-12 烷基，(R3)b 代表 0 至 4 个取代基，如卤素原子，R4 代表低级烷基，R5 代表氢原子或低级烷基，n 代表 2 至 4 的整数、X代表-NH-或-O-，它具有优异的降血糖作用、降血脂作用和降低总胆固醇作用，可用作预防和/或治疗糖尿病、高脂血症等疾病的药物活性成分。